Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101.
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2016
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Biliary cancer; Liver cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Apr 2011 Planned end date changed from 1 Feb 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
- 05 Aug 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.